International Journal of Urology最新文献

英文中文

Editorial Comment on “Herpes zoster development in living kidney transplant recipients receiving low-dose rituximab” 关于 "接受低剂量利妥昔单抗的活体肾移植受者出现带状疱疹 "的编辑评论。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-08 DOI: 10.1111/iju.15633

Takafumi Yagisawa MD, PhD, Hideki Ishida MD, PhD, Toshio Takagi MD, PhD

引用次数: 0

Acknowledgment 鸣谢

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-07 DOI: 10.1111/iju.15626

引用次数: 0

Efficacy and safety of prostatic urethral lift according to preoperative urinary retention and prostate volume: A Japanese real-world multicenter data 根据术前尿潴留和前列腺体积确定前列腺尿道上提术的有效性和安全性：日本多中心真实数据。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-05 DOI: 10.1111/iju.15621

Go Anan, Hidero Minami, Yosuke Fujishima, Kanya Kaga

Objectives

Prostatic urethral lift (PUL) for benign prostatic hyperplasia has recently been initiated in Asia; therefore, few studies with real-world data have been reported. This study evaluated the efficacy and safety of PUL using Japanese real-world multicenter data.

Methods

Indications for PUL were based on relevant guidelines in Japan. The preoperative patient status, postoperative progress at 1 and 3 months, and perioperative complications were evaluated. Also, we compared preoperative urinary retention and nonurinary retention patients, and prostate volumes <30, 30 to <50, and ≥50 mL.

Results

A total of 160 patients were included in the study. The mean age was 75 years and the mean prostate volume was 44 mL. The International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual volume significantly improved 1 and 3 months postoperatively compared to preoperatively. The catheter-free rates in the preoperative urinary retention group were 58.1%, 72.1%, 83.7%, and 88.4% on postoperative days 1, 7, 30, and 90, respectively. The catheter-free rates in the nonurinary retention group were 94.9%, 98.3%, and 100% on postoperative days 1, 7, and 14, respectively. The group with a prostate volume ≥50 mL had a longer operation time and used significantly more implants; however, no difference was observed in the postoperative urinary status among the three groups.

Conclusions

PUL can be considered a safe and effective procedure for both preoperative urinary retention and nonurinary retention patients with prostate volumes <100 mL in older patients with comorbidities.

目的：前列腺尿道上提（PUL）治疗良性前列腺增生症最近才在亚洲开始，因此，很少有关于真实世界数据的研究报道。本研究利用日本多中心真实数据评估了前列腺尿道上提术的疗效和安全性：方法：PUL 的适应症基于日本的相关指南。方法：PUL 的适应症以日本的相关指南为基础，评估了患者的术前状态、术后 1 个月和 3 个月的进展情况以及围手术期并发症。此外，我们还比较了术前尿潴留和非尿潴留患者以及前列腺体积：本研究共纳入 160 名患者。平均年龄为 75 岁，平均前列腺体积为 44 毫升。与术前相比，术后 1 个月和 3 个月的国际前列腺症状评分、生活质量评分、最大尿流率和排尿后残余尿量均有明显改善。术前尿潴留组在术后第 1、7、30 和 90 天的无导尿管率分别为 58.1%、72.1%、83.7% 和 88.4%。无尿潴留组在术后第 1、7 和 14 天的无导尿管率分别为 94.9%、98.3% 和 100%。前列腺体积≥50 mL组的手术时间更长，使用的植入物也明显更多；不过，三组患者的术后排尿状况没有差异：对于术前有尿潴留和无尿潴留的前列腺体积≥50 mL 的患者，PUL 可被视为一种安全有效的手术。

{"title":"Efficacy and safety of prostatic urethral lift according to preoperative urinary retention and prostate volume: A Japanese real-world multicenter data","authors":"Go Anan, Hidero Minami, Yosuke Fujishima, Kanya Kaga","doi":"10.1111/iju.15621","DOIUrl":"10.1111/iju.15621","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Prostatic urethral lift (PUL) for benign prostatic hyperplasia has recently been initiated in Asia; therefore, few studies with real-world data have been reported. This study evaluated the efficacy and safety of PUL using Japanese real-world multicenter data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Indications for PUL were based on relevant guidelines in Japan. The preoperative patient status, postoperative progress at 1 and 3 months, and perioperative complications were evaluated. Also, we compared preoperative urinary retention and nonurinary retention patients, and prostate volumes <30, 30 to <50, and ≥50 mL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 160 patients were included in the study. The mean age was 75 years and the mean prostate volume was 44 mL. The International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual volume significantly improved 1 and 3 months postoperatively compared to preoperatively. The catheter-free rates in the preoperative urinary retention group were 58.1%, 72.1%, 83.7%, and 88.4% on postoperative days 1, 7, 30, and 90, respectively. The catheter-free rates in the nonurinary retention group were 94.9%, 98.3%, and 100% on postoperative days 1, 7, and 14, respectively. The group with a prostate volume ≥50 mL had a longer operation time and used significantly more implants; however, no difference was observed in the postoperative urinary status among the three groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PUL can be considered a safe and effective procedure for both preoperative urinary retention and nonurinary retention patients with prostate volumes <100 mL in older patients with comorbidities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"190-197"},"PeriodicalIF":1.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.15621","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful kidney transplantation improves atrophic bladder capacity and function within 3 months in long-term dialysis patients 成功的肾移植可在 3 个月内改善长期透析患者的萎缩性膀胱容量和功能。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-05 DOI: 10.1111/iju.15589

Tatsuya Hoshi MD, Takayuki Hirose MD, PhD, Kanako Fuyama M.Sc., Naoya Iwahara MD, PhD, Hiroki Chiba MD, PhD, Kiyohiko Hotta MD, PhD

引用次数: 0

This issue 31–11 本期 31-11。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-02 DOI: 10.1111/iju.15584

Norihiko Tsuchiya M.D.

引用次数: 0

Long-term outcomes of transvaginal mesh surgery for pelvic organ prolapse at a single center in Japan. 日本单个中心经阴道网片手术治疗盆腔器官脱垂的长期疗效。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-11-02 DOI: 10.1111/iju.15630

Chikako Kato, Tomoko Kuwata, Hiromi Kashihara, Masami Takeyama

Objectives: This study aimed to investigate the long-term effectiveness and safety of transvaginal mesh surgery for pelvic organ prolapse at a high-volume center in Japan.

Methods: Patients who underwent transvaginal mesh surgery between March 2010 and August 2015 were included and followed up for 5 years. As no mesh kits were available in our country, we used a self-cut polypropylene mesh (Japanese-style transvaginal mesh) for the procedures. Objective anatomical restoration and complications were evaluated during outpatient examinations.

Results: Overall, 711 patients were included in this study. Over 5 years, the recurrence rate of stage 2 or higher prolapse at the operated compartment was 8.6% (61 cases), whereas that at the other compartments was 12.8% (91 cases). The frequency of recurrence was highest at 3 months and decreased with each passing year in both compartments. During the follow-up period, 28 patients (three at the operated compartment and 25 at the other compartments) required reoperation owing to recurrence. Overall, there were 13 cases of mesh exposure (1.8%), including two (0.28%) in the bladder, 10 (1.4%) in the vagina, and one (0.14%) in the rectum. Urinary incontinence surgery was performed in 69 patients (9.7%) during the follow-up period.

Conclusions: The frequencies of recurrence requiring reoperation and mesh-related complications were low, and vaginal mesh exposure was mostly asymptomatic. Therefore, the Japanese-style transvaginal mesh is safe and effective.

研究目的本研究旨在调查日本一家高产量中心经阴道网片手术治疗盆腔器官脱垂的长期有效性和安全性：纳入2010年3月至2015年8月期间接受经阴道网片手术的患者，并随访5年。由于我国没有网片套件，我们在手术中使用了自切聚丙烯网片（日式经阴道网片）。在门诊检查中对客观解剖恢复和并发症进行评估：结果：本研究共纳入 711 例患者。5 年内，手术区 2 期或 2 期以上脱垂的复发率为 8.6%（61 例），而其他区域的复发率为 12.8%（91 例）。两个区段的复发频率在 3 个月时最高，随着时间的推移逐年降低。在随访期间，有 28 例患者（3 例在手术区，25 例在其他区）因复发而需要再次手术。共有 13 例网片外露（1.8%），其中膀胱 2 例（0.28%），阴道 10 例（1.4%），直肠 1 例（0.14%）。69名患者（9.7%）在随访期间接受了尿失禁手术：结论：需要再次手术的复发率和网片相关并发症的发生率较低，阴道网片暴露大多无症状。因此，日式经阴道网片是安全有效的。

{"title":"Long-term outcomes of transvaginal mesh surgery for pelvic organ prolapse at a single center in Japan.","authors":"Chikako Kato, Tomoko Kuwata, Hiromi Kashihara, Masami Takeyama","doi":"10.1111/iju.15630","DOIUrl":"https://doi.org/10.1111/iju.15630","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the long-term effectiveness and safety of transvaginal mesh surgery for pelvic organ prolapse at a high-volume center in Japan.</p><p><strong>Methods: </strong>Patients who underwent transvaginal mesh surgery between March 2010 and August 2015 were included and followed up for 5 years. As no mesh kits were available in our country, we used a self-cut polypropylene mesh (Japanese-style transvaginal mesh) for the procedures. Objective anatomical restoration and complications were evaluated during outpatient examinations.</p><p><strong>Results: </strong>Overall, 711 patients were included in this study. Over 5 years, the recurrence rate of stage 2 or higher prolapse at the operated compartment was 8.6% (61 cases), whereas that at the other compartments was 12.8% (91 cases). The frequency of recurrence was highest at 3 months and decreased with each passing year in both compartments. During the follow-up period, 28 patients (three at the operated compartment and 25 at the other compartments) required reoperation owing to recurrence. Overall, there were 13 cases of mesh exposure (1.8%), including two (0.28%) in the bladder, 10 (1.4%) in the vagina, and one (0.14%) in the rectum. Urinary incontinence surgery was performed in 69 patients (9.7%) during the follow-up period.</p><p><strong>Conclusions: </strong>The frequencies of recurrence requiring reoperation and mesh-related complications were low, and vaginal mesh exposure was mostly asymptomatic. Therefore, the Japanese-style transvaginal mesh is safe and effective.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Comments on “Exploring the association between chronic prostatitis and the risk of herpes zoster in a cohort study in Taiwan” 关于 "台湾一项队列研究探讨慢性前列腺炎与带状疱疹风险之间的关系 "的编辑评论

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-10-31 DOI: 10.1111/iju.15629

Tomohiro Matsuo MD, PhD, Ryoichi Imamura MD, PhD

引用次数: 0

Recent advances in basic research on prostate cancer: Where we are heading? 前列腺癌基础研究的最新进展：我们将何去何从？

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-10-30 DOI: 10.1111/iju.15628

Daisuke Obinata, Yasutaka Yamada, Takayuki Sumiyoshi, Tokiyoshi Tanegashima, Ryuta Watanabe, Hiroaki Kobayashi, Daisuke Ito, Fumihiko Urabe

In the over 80 years since androgens were found to play a pivotal role in prostate cancer (PCa) progression, androgen deprivation therapy (ADT) has been a cornerstone in treating advanced PCa. Castration-resistant PCa persists, however, with some of these tumors evolving to androgen receptor (AR)-independent forms like neuroendocrine PCa. The development of novel diagnostic and therapeutic approaches to PCa is therefore crucial. This review provides an overview of recent basic research in PCa, focusing on two main areas: PCa cells and their tumor microenvironments. The first section describes current knowledge on the intricate mechanisms of AR signaling pathways, emphasizing the roles of coactivators and chromatin state alterations in gene regulation. Genomic analyses have revealed recurrent mutations and copy number alterations critical for precision medicine. Liquid biopsy has become a promising tool for real-time tumor monitoring, identifying genetic alterations in circulating-tumor DNA or extracellular vesicles. The second section describes the tumor microenvironment of PCa, highlighting its immunosuppressive landscape and the potential of combining ADT with immunotherapy. Advanced techniques, including single-cell RNA sequencing and spatial transcriptomics offer insights into cellular heterogeneity and interactions within the tumor microenvironment, paving the way for novel therapeutic strategies. Integration of these diverse research areas will provide a comprehensive understanding of the current state and future directions of PCa research, underscoring the importance of personalized medicine and the dynamic nature of cancer treatment strategies.

自从发现雄激素在前列腺癌（PCa）进展中起关键作用以来的 80 多年里，雄激素剥夺疗法（ADT）一直是治疗晚期 PCa 的基石。然而，阉割耐药PCa仍然存在，其中一些肿瘤演变为雄激素受体（AR）依赖型，如神经内分泌型PCa。因此，开发新的PCa诊断和治疗方法至关重要。本综述概述了 PCa 的最新基础研究，重点关注两个主要领域：PCa 细胞及其肿瘤微环境。第一部分介绍了目前有关 AR 信号通路复杂机制的知识，强调了共激活剂和染色质状态改变在基因调控中的作用。基因组分析揭示了对精准医疗至关重要的复发性突变和拷贝数改变。液体活检已成为一种很有前途的实时肿瘤监测工具，它能识别循环肿瘤DNA或细胞外囊泡中的基因改变。第二部分介绍了 PCa 的肿瘤微环境，强调了其免疫抑制状况以及 ADT 与免疫疗法相结合的潜力。单细胞 RNA 测序和空间转录组学等先进技术有助于深入了解肿瘤微环境中的细胞异质性和相互作用，为新型治疗策略铺平道路。整合这些不同的研究领域将使人们对 PCa 研究的现状和未来方向有一个全面的了解，同时强调个性化医疗的重要性和癌症治疗策略的动态性。

{"title":"Recent advances in basic research on prostate cancer: Where we are heading?","authors":"Daisuke Obinata, Yasutaka Yamada, Takayuki Sumiyoshi, Tokiyoshi Tanegashima, Ryuta Watanabe, Hiroaki Kobayashi, Daisuke Ito, Fumihiko Urabe","doi":"10.1111/iju.15628","DOIUrl":"https://doi.org/10.1111/iju.15628","url":null,"abstract":"<p><p>In the over 80 years since androgens were found to play a pivotal role in prostate cancer (PCa) progression, androgen deprivation therapy (ADT) has been a cornerstone in treating advanced PCa. Castration-resistant PCa persists, however, with some of these tumors evolving to androgen receptor (AR)-independent forms like neuroendocrine PCa. The development of novel diagnostic and therapeutic approaches to PCa is therefore crucial. This review provides an overview of recent basic research in PCa, focusing on two main areas: PCa cells and their tumor microenvironments. The first section describes current knowledge on the intricate mechanisms of AR signaling pathways, emphasizing the roles of coactivators and chromatin state alterations in gene regulation. Genomic analyses have revealed recurrent mutations and copy number alterations critical for precision medicine. Liquid biopsy has become a promising tool for real-time tumor monitoring, identifying genetic alterations in circulating-tumor DNA or extracellular vesicles. The second section describes the tumor microenvironment of PCa, highlighting its immunosuppressive landscape and the potential of combining ADT with immunotherapy. Advanced techniques, including single-cell RNA sequencing and spatial transcriptomics offer insights into cellular heterogeneity and interactions within the tumor microenvironment, paving the way for novel therapeutic strategies. Integration of these diverse research areas will provide a comprehensive understanding of the current state and future directions of PCa research, underscoring the importance of personalized medicine and the dynamic nature of cancer treatment strategies.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142545427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial Comment on Underactive bladder as defined by the International Continence Society in the 2023 Japan Community Health Survey 关于国际尿失禁协会在 2023 年日本社区健康调查中定义的膀胱功能不全的编辑评论。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-10-28 DOI: 10.1111/iju.15623

Tomohiro Matsuo MD, PhD, Ryoichi Imamura MD, PhD

引用次数: 0

Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study 肾切除术治疗肾细胞癌的生存率随时间推移而提高：倾向评分匹配纵向研究。

IF 1.8 3区医学 Q3 UROLOGY & NEPHROLOGY

International Journal of Urology

Pub Date : 2024-10-28 DOI: 10.1111/iju.15610

Kenjiro Kishitani, Satoru Taguchi, Koji Tanaka, Tetsuya Danno, Takahiro Oshina, Yoichi Fujii, Jun Kamei, Yoshiyuki Akiyama, Shigenori Kakutani, Yusuke Sato, Yuta Yamada, Aya Niimi, Daisuke Yamada, Haruki Kume

Objective

Surgical treatment for renal cell carcinoma (RCC) has drastically evolved for the past 30 years. However, survival outcomes of RCC according to times have not been fully elucidated, especially in the real-world setting. This study aimed to assess the survival improvement over time in RCC treated with nephrectomy by analyzing a longitudinal cohort using propensity score matching (PSM).

Methods

We retrospectively reviewed 960 patients with RCC who underwent radical or partial nephrectomy between 1981 and 2018. Patients were divided into two groups according to the time of surgery (1981–1999 vs. 2000–2018). Using PSM, overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were compared between the two groups.

Results

Overall, 255 and 705 patients underwent surgery in the earlier (1981–1999) and recent (2000–2018) eras, and PSM derived a matched cohort of 466 patients (233 patients per each group). All patients in the earlier era cohort received open surgeries, whereas about a half (47.4%) of patients in the recent era cohort received minimally-invasive (laparoscopic/robotic) surgeries. After PSM, 137 (29.4%) patients developed recurrence, 105 (22.5%) died of RCC, and 113 (24.2%) died from other causes, with a median follow-up period of 90 months. The recent era cohort had significantly longer OS, CSS, and RFS than the earlier era cohort.

Conclusions

Patients with RCC treated in the recent era (2000–2018) showed significantly longer survival than those treated in the earlier era (1981–1999). The improved survival might be attributable to the prevalence of minimally-invasive (laparoscopic/robotic) surgeries.

目的：在过去的 30 年中，肾细胞癌（RCC）的手术治疗发生了翻天覆地的变化。然而，RCC 随时间变化的生存结果尚未完全阐明，尤其是在现实世界中。本研究旨在通过使用倾向评分匹配（PSM）分析纵向队列，评估接受肾切除术治疗的 RCC 随时间推移的生存率改善情况：我们回顾性研究了1981年至2018年间接受根治性或部分肾切除术的960例RCC患者。根据手术时间（1981-1999年与2000-2018年）将患者分为两组。使用PSM比较两组患者的总生存期（OS）、癌症特异性生存期（CSS）和无复发生存期（RFS）：总体而言，早期（1981-1999 年）和近期（2000-2018 年）分别有 255 名和 705 名患者接受了手术，PSM 得出了 466 名患者的匹配队列（每组 233 名患者）。早期队列中的所有患者都接受了开腹手术，而近期队列中约有一半（47.4%）的患者接受了微创（腹腔镜/机器人）手术。PSM术后，137例（29.4%）患者复发，105例（22.5%）死于RCC，113例（24.2%）死于其他原因，中位随访时间为90个月。近代队列的OS、CSS和RFS明显长于早期队列：结论：近期（2000-2018 年）接受治疗的 RCC 患者的生存期明显长于早期（1981-1999 年）接受治疗的患者。生存率的提高可能与微创（腹腔镜/机器人）手术的普及有关。

{"title":"Survival improvement over time in renal cell carcinoma treated with nephrectomy: A longitudinal propensity score-matched study","authors":"Kenjiro Kishitani, Satoru Taguchi, Koji Tanaka, Tetsuya Danno, Takahiro Oshina, Yoichi Fujii, Jun Kamei, Yoshiyuki Akiyama, Shigenori Kakutani, Yusuke Sato, Yuta Yamada, Aya Niimi, Daisuke Yamada, Haruki Kume","doi":"10.1111/iju.15610","DOIUrl":"10.1111/iju.15610","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Surgical treatment for renal cell carcinoma (RCC) has drastically evolved for the past 30 years. However, survival outcomes of RCC according to times have not been fully elucidated, especially in the real-world setting. This study aimed to assess the survival improvement over time in RCC treated with nephrectomy by analyzing a longitudinal cohort using propensity score matching (PSM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed 960 patients with RCC who underwent radical or partial nephrectomy between 1981 and 2018. Patients were divided into two groups according to the time of surgery (1981–1999 vs. 2000–2018). Using PSM, overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) were compared between the two groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, 255 and 705 patients underwent surgery in the earlier (1981–1999) and recent (2000–2018) eras, and PSM derived a matched cohort of 466 patients (233 patients per each group). All patients in the earlier era cohort received open surgeries, whereas about a half (47.4%) of patients in the recent era cohort received minimally-invasive (laparoscopic/robotic) surgeries. After PSM, 137 (29.4%) patients developed recurrence, 105 (22.5%) died of RCC, and 113 (24.2%) died from other causes, with a median follow-up period of 90 months. The recent era cohort had significantly longer OS, CSS, and RFS than the earlier era cohort.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with RCC treated in the recent era (2000–2018) showed significantly longer survival than those treated in the earlier era (1981–1999). The improved survival might be attributable to the prevalence of minimally-invasive (laparoscopic/robotic) surgeries.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"32 2","pages":"145-150"},"PeriodicalIF":1.8,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/iju.15610","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

International Journal of Urology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀